DISCO’s AND-gated bispecific concept is designed to widen target access while aiming to reduce on-target off-tumor toxicity through dual-antigen engagement logic. The approach depends on cell-surface expression mapping and binding only when both targets co-occur on tumor cells. Complementing the platform story, a study in nasopharyngeal carcinoma linked CD44 expression with viral oncoprotein LMP1, suppressed tumor-infiltrating killer T cells, and reduced combined PD-L1 scores, pointing to a biomarker-linked immune suppression phenotype. For oncology development teams, these two pieces jointly sharpen the biomarker question: surface targeting strategies may need patient stratification anchored in immune-context readouts like T-cell infiltration and PD-L1 activity.
Get the Daily Brief